0. DOCID:26937 SCORE: 0.00354798978123113
DOCNO: 10940507
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Polymorphism, Genetic
QUALIFIER: genetics
QUALIFIER: genetics
AUTHOR: I Saadat I
AUTHOR: M Saadat M
AFFILIATION: Department of Biology, College of Sciences, Shiraz University, 71454, Shiraz, Iran.
PUBTYPE: Journal Article
JOURNALTITLE: Cancer letters.
COUNTRY: IRELAND
TITLE: The glutathione S-transferase mu polymorphism and susceptibility to acute lymphocytic leukemia.
PUBDATE: 20000901
It has been postulated that the absence of glutathione S-transferase mu (GSTmu), which impairs detoxification of some carcinogens, might predispose some individuals to the development of certain cancers. In the present study, polymorphism of GSTM1 were detected by polymerase chain reaction (PCR) in 38 patients with acute lymphocytic leukemia and 75 normal subjects. The null genotype of GSTM1 was significantly more common among leukemic patients compared with the normal control group (55.3 vs. 32.0%; P<0.025). The absence of the GSTmu enzyme may increase the risk of the development of leukemia.


1. DOCID:29566 SCORE: 0.00310903926299525
DOCNO: 14722609
AUTHOR: Bruce E Kemp BE
AFFILIATION: St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia. kemp@ariel.unimelb.edu.au
PUBTYPE: Comment
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: The Journal of clinical investigation.
COUNTRY: United States
TITLE: Bateman domains and adenosine derivatives form a binding contract.
PUBDATE: 20040101
Conserved pairs of CBS sequence motifs (named after cystathionine beta-synthase) found in a wide variety of proteins associate to form Bateman domains. A new study establishes that Bateman domains bind adenosyl compounds and regulate IMP dehydrogenase, CBS, chloride channels, and AMP-activated protein kinase. This discovery reveals how mutations in CBS sequences in these proteins cause hereditary diseases and provides a rich vista of conceptual opportunities for therapies in energy metabolism, obesity, diabetes, cancer, antivirals, and immunosuppression.


2. DOCID:24724 SCORE: 0.00286846808172891
DOCNO: 10860214
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Double Effect
DESCRIPTOR: Ethics
DESCRIPTOR: Ethics, Medical
DESCRIPTOR: Intention
QUALIFIER: legislation & jurisprudence
QUALIFIER: legislation & jurisprudence
AUTHOR: C E Kendall CE
AFFILIATION: St Peter's Hospice, Bristol.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Journal of medical ethics.
COUNTRY: ENGLAND
TITLE: At the coalface: medical ethics in practice. A double dose of double effect.
PUBDATE: 20000601
This paper presents a clinically orientated illustration of the doctrine of double effect. The case of an elderly gentleman with advanced cancer is discussed, with particular emphasis on two dilemmas encountered during the terminal phase of his illness. The author describes how the doctrine of double effect was applied to help the team make some complex management decisions.


3. DOCID:27319 SCORE: 0.00265910832642292
DOCNO: 10448183
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapy
AUTHOR: J Moppett J
AUTHOR: I Haddadin I
AUTHOR: A B Foot AB
AFFILIATION: The Royal Hospital for Sick Children St Michael's Hill Bristol BS2 8BJ.
PUBTYPE: Journal Article
JOURNALTITLE: Archives of disease in childhood. Fetal and neonatal edition.
COUNTRY: ENGLAND
TITLE: Neonatal neuroblastoma.
PUBDATE: 19990901
Over nine years, 33 children with neonatal neuroblastoma were registered with the UKCCSG (United Kingdom Children's Cancer Study Group). Tumours of all stages were found, but stage 4S disease predominated. Five tumours were detected prenatally by ultrasonography. Treatment varied according to tumour stage. The overall survival of the group was 91%. Ten children have had long term complications as a result of their disease, usually as a result of spinal tumour involvement. The good overall prognosis in this age group is encouraging, but the poor neurological outcome of patients with intraspinal extension is of concern.


4. DOCID:27232 SCORE: 0.00265910785423408
DOCNO: 14659026
OWNER: NLM
STATUS: PubMed-not-MEDLINE
AUTHOR: C P Schultheis CP
AUTHOR: M A Raheem MA
AUTHOR: M C Perry MC
AFFILIATION: University of Missouri/Ellis Fischel Cancer Center, Columbia, Missouri 65203, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Clinical lung cancer.
COUNTRY: United States
TITLE: Second-line chemotherapy for small-cell lung cancer: a review.
PUBDATE: 20011101
Small-cell lung cancer (SCLC) is an aggressive malignancy, and only a minority of patients survive 2 years. Although this cancer is sensitive to both chemotherapy and radiotherapy, the majority of patients relapse, and second-line treatment is an option for many. Currently in the United States, the combination of cisplatin/etoposide is the standard first-line therapy in SCLC. At this time, topotecan is the only Food and Drug Administration-approved chemotherapeutic agent for second-line treatment of SCLC. In this paper, we review studies of second-line chemotherapy for SCLC.


5. DOCID:26694 SCORE: 0.00258279236426558
DOCNO: 11249681
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: pharmacology
QUALIFIER: genetics
QUALIFIER: pharmacology
AUTHOR: G Forni G
AUTHOR: K Boggio K
AFFILIATION: Department of Clinical and Biological Sciences, University of Turin, Ospedale San Luigi Gonzaga, 10043 Orbassano, Italy. forni@pasteur.sluigi.unito.it
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in molecular therapeutics.
COUNTRY: England
TITLE: Cytokine gene-engineered vaccines.
PUBDATE: 19990201
Cytokines modulate immune reactivity and have therefore been used to build cancer vaccines. Experimental vaccination of rodents and humans with cytokine-gene engineered tumor cells, fusion proteins between cytokines and tumor antigens, and their DNA have been shown to induce a significant immune memory, even against poorly immunogenic tumors. This immune memory can prevent tumor growth and cure initial metastases, but is poorly effective against established tumors. To date clinical trials have been confined to patients with advanced tumors; so far they suggest that this approach is safe.


6. DOCID:29165 SCORE: 0.00258191354686006
DOCNO: 15854985
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: surgery
QUALIFIER: surgery
QUALIFIER: therapeutic use
QUALIFIER: secondary
AUTHOR: Yoshinobu Ichiki Y
AUTHOR: Masaru Morita M
AUTHOR: Koichi Yano K
AUTHOR: Kenji Sugio K
AUTHOR: Kosei Yasumoto K
AUTHOR: Naofumi Hirose N
AFFILIATION: Second Department of Surgery, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan. y-ichiki@med.uoeh-u.ac.jp
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: The Annals of thoracic surgery.
COUNTRY: Netherlands
TITLE: Iris metastasis of esophageal cancer.
PUBDATE: 20050501
Ocular metastasis in patients with esophageal cancer is quite rare. Several cases have been reported in the literature, but no successful treatments for such metastases have ever been described. We herein report a case of esophageal cancer in which the ocular metastasis was controlled by systemic chemotherapy.


7. DOCID:28991 SCORE: 0.00258191304676728
DOCNO: 16137795
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Maria Teresa Cocco MT
AUTHOR: Cenzo Congiu C
AUTHOR: Valentina Lilliu V
AUTHOR: Valentina Onnis V
AFFILIATION: Dipartimento di Tossicologia, Università degli Studi di Cagliari, Via Ospedale 72-09124 Cagliari, Italy.
PUBTYPE: Journal Article
JOURNALTITLE: European journal of medicinal chemistry.
COUNTRY: France
TITLE: Synthesis and antiproliferative activity of 2,6-Dibenzylamino-3,5-dicyanopyridines on human cancer cell lines.
PUBDATE: 20051201
A new series of 2,6-dibenzylamino-3,5-dicyanopyridines were synthesized and evaluated for their in vitro anticancer activity toward cell lines of nine different types of human cancer. Some of newly prepared compounds demonstrated remarkable anticancer activity against most of the tested subpanel tumor cell lines.


8. DOCID:29441 SCORE: 0.00257479317696229
DOCNO: 12671668
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: methods
QUALIFIER: diagnosis
QUALIFIER: prevention & control
AUTHOR: Michael N Pollak MN
AUTHOR: William D Foulkes WD
AFFILIATION: Programs of Cancer Prevention and Cancer Genetics, McGill University, Montreal, Quebec, Canada H3T 1E2. michael.pollak@mcgill.ca
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature reviews. Cancer.
COUNTRY: England
TITLE: Challenges to cancer control by screening.
PUBDATE: 20030401
Population-based screening seems to be a common-sense strategy for controlling cancer, but recent reports have raised controversy concerning the benefits of common screening procedures. Intense efforts to develop and evaluate novel screening technologies are underway; however, effective use of any screening method must take into account any underlying biological considerations. What are these biological issues, and what challenges do clinicians face in screening for common cancers?


9. DOCID:27938 SCORE: 0.00253207957635948
DOCNO: 10431670
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: adverse effects
QUALIFIER: prevention & control
AUTHOR: E M McCarthy EM
AUTHOR: K P Ethridge KP
AUTHOR: R F Wagner RF
AFFILIATION: Department of Dermatology, University of Texas Medical Branch, Galveston 77555-0783, USA.
PUBTYPE: Journal Article
JOURNALTITLE: Cutis; cutaneous medicine for the practitioner.
COUNTRY: UNITED STATES
TITLE: Beach holiday sunburn: the sunscreen paradox and gender differences.
PUBDATE: 19990701
A survey about sunbathing practices was performed on a summer holiday weekend at a Galveston beach. The likelihood of sunburn increased with increasing duration of sun exposure, with 100% of subjects experiencing sunburn after exposure > or = 4.5 hours. Men exhibited a significantly higher frequency of sunburn, employed fewer sun-protective measures, and demonstrated less knowledge concerning sun safety information and skin cancer than women. This information suggests a need for greater educational efforts directed toward changing public attitudes about preventing sunburn, especially those of men, that currently lead to high-risk sunbathing behavior.


10. DOCID:28566 SCORE: 0.00242455394576935
DOCNO: 14730469
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: adverse effects
QUALIFIER: analogs & derivatives
QUALIFIER: therapeutic use
QUALIFIER: chemically induced
QUALIFIER: drug therapy
AUTHOR: R Todd Reilly RT
AFFILIATION: The Johns Hopkins School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street Room 4M08, Baltimore, MD 21231, USA. reilly@jhmi.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: IDrugs : the investigational drugs journal.
COUNTRY: England
TITLE: BNP-7787 (BioNumerik/Baxter Oncology/Grelan).
PUBDATE: 20040101
BioNumerik Pharmacology Inc, Baxter Oncology GmbH (formerly ASTA Medica AG) and Grelan Pharmaceutical Co Ltd are developing BNP-7787 for the potential reduction of toxicity associated with cisplatin and carboplatin treatment in cancer patients.


11. DOCID:27955 SCORE: 0.00238011860725909
DOCNO: 9656791
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: etiology
QUALIFIER: metabolism
QUALIFIER: physiology
AUTHOR: T I Andersen TI
AFFILIATION: Avdeling for medisinsk genetikk Ullevål sykehus, Blindern, Oslo.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Tidsskrift for den Norske laegeforening.
COUNTRY: NORWAY
TITLE: [Telomeres, telomerase and development of cancer]
PUBDATE: 19980501
The chromosome ends, telomeres, shorten during each cell division due to the inability of DNA polymerase to replicate the ends of linear chromosomes. The telomere length serves as a clock determining the remaining replicative capacity of the cell. After 50-100 doublings, the cell becomes senescent. Rarely, a cell overcomes the senescence blockade, and eventually becomes immortal. Cellular immortalisation is almost always accompanied by the expression of the enzyme telomerase, which synthesises telomeric DNA. Telomerase is present in approximately 85% of malignancies. The detection of telomerase activity in cancer cells represents a possible cancer diagnostic and prognostic tool, and telomerase inhibition may become a novel therapeutic strategy in cancer patients.


12. DOCID:31254 SCORE: 0.00237460117500248
DOCNO: 15886702
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: genetics
QUALIFIER: adverse effects
QUALIFIER: etiology
QUALIFIER: genetics
AUTHOR: C Lilla C
AUTHOR: T Koehler T
AUTHOR: S Kropp S
AUTHOR: S Wang-Gohrke S
AUTHOR: J Chang-Claude J
AFFILIATION: Division of Clinical Epidemiology, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, Heidelberg 69120, Germany.
PUBTYPE: Journal Article
JOURNALTITLE: British journal of cancer.
COUNTRY: England
TITLE: Alcohol dehydrogenase 1B (ADH1B) genotype, alcohol consumption and breast cancer risk by age 50 years in a German case-control study.
PUBDATE: 20050601
In a population-based study of 613 cases and 1082 controls, alcohol dehydrogenase 1B (ADH1B) genotype was not an independent risk factor for breast cancer, although the possibility was raised that it modifies risk associated with high levels of alcohol consumption (OR 1.1, 95% confidence interval (CI) 0.8-1.6 for ADH1B*1/*1 genotype vs 0.2, 95% CI 0.1-1.0 for ADH1B*2 carriers).


13. DOCID:26567 SCORE: 0.00226593597373778
DOCNO: 11354372
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: chemical synthesis
QUALIFIER: pharmacology
QUALIFIER: chemical synthesis
QUALIFIER: pharmacology
QUALIFIER: chemical synthesis
QUALIFIER: pharmacology
AUTHOR: F M Uckun FM
AUTHOR: C J Forsyth CJ
AFFILIATION: Parker Hughes, Cancer Center, Department of Oncology and Drug Discovery Program, Parker Hughes Institute, St. Paul, MN 55113, USA. faith_uckun@ih.org
PUBTYPE: Journal Article
JOURNALTITLE: Bioorganic & medicinal chemistry letters.
COUNTRY: England
TITLE: Anticancer activity of synthetic analogues of the phorboxazoles.
PUBDATE: 20010501
The phorboxazoles are recently described natural products that are extremely cytostatic towards the National Cancer Institute's panel of 60 tumor cell lines. We report here the results of preliminary structure-activity studies of synthetic analogues of the phorboxazoles against BT-20 breast cancer, NALM-6 B-lineage ALL, U373 brain tumor, and U373 glioblastoma cell lines. These data indicate the importance of several of the natural products' structural moieties for potent anticancer activity.


14. DOCID:26846 SCORE: 0.0022657190910022
DOCNO: 11019375
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: complications
QUALIFIER: etiology
QUALIFIER: etiology
QUALIFIER: complications
AUTHOR: T Abe T
AUTHOR: S Konari S
AUTHOR: W Obara W
AUTHOR: T Okamoto T
AUTHOR: T Fujioka T
AFFILIATION: Department of Urology, Iwate Prefectual Senmaya Hospital.
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Hinyokika kiyo. Acta urologica Japonica.
COUNTRY: JAPAN
TITLE: [A case of squamous cell carcinoma arising in the urinary bladder diverticulum]
PUBDATE: 20000801
A 49-year-old man was admitted to our hospital with the chief compliant of difficulty of urination, lower abdominal pain and macrohematuria. On cystoscopy, a non-papillary tumor was seen in the diverticulum on the right side of the urinary bladder. Having made the diagnosis of urinary bladder cancer, we performed total cystectomy, retroperitoneal node dissection and construction of an ileal neobladder. Histologically, it was squamous cell carcinoma, pT3a, pN0. Seven months after the operation, the patient died of recurrent disease.